+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Integrin Inhibitors Market - Global Forecast 2026-2032- Product Image
Integrin Inhibitors Market - Global Forecast 2026-2032- Product Image
Sale

Integrin Inhibitors Market - Global Forecast 2026-2032

  • Report

  • 195 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6118432
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Integrin Inhibitors Market is projected to reach USD 3.43 Billion in 2026. It is expected to continue growing at a CAGR of 10.08%, reaching USD 6.12 Billion by 2032.

Integrin Inhibitors: Executive Overview

Integrin inhibitors are a targeted therapeutic approach focused on disrupting integrin-mediated signaling and cell adhesion. Their relevance spans inflammatory, autoimmune, fibrotic, vascular, and oncology research, where integrins can influence immune-cell trafficking, tissue remodeling, angiogenesis, and tumor-cell behavior. The field is shaped by the need to balance pathway selectivity, clinical benefit, safety, and durable treatment response.

Shifting From Broad Blockade to Selective Integrin Modulation

The landscape is moving toward greater biological precision. Research increasingly distinguishes among integrin subtypes, ligand interactions, tissue expression, and disease-specific mechanisms rather than treating integrins as a single target class. Translational work is also emphasizing biomarker-led patient selection, improved understanding of on-target safety risks, and combination strategies that address complementary disease pathways. These shifts are encouraging more differentiated development programs and closer integration between molecular biology, clinical pharmacology, and real-world treatment considerations.

Artificial Intelligence Accelerates Target and Biomarker Discovery

Artificial intelligence can support integrin-inhibitor development by integrating omics, imaging, structural, clinical, and safety datasets. Potential applications include identifying disease-relevant integrin signatures, prioritizing molecular designs, modeling ligand interactions, detecting response subgroups, and improving trial-site or patient-selection strategies. Its value depends on validated datasets, transparent model performance, prospective clinical testing, and careful control of bias. AI should therefore be used as a decision-support capability rather than a substitute for mechanistic validation or clinical evidence.

Regional Insights Across the Global Development Landscape

North America is supported by strong biomedical research infrastructure, specialist clinical networks, and advanced translational capabilities. Europe benefits from coordinated scientific collaboration, established regulatory systems, and substantial interest in immune-mediated and rare diseases. Asia-Pacific combines expanding clinical research capacity with major biomedical centers in countries such as China, Japan, South Korea, Australia, and India. Latin America presents opportunities for investigator-led research and broader access initiatives, while clinical execution may require attention to healthcare-system variation. The Middle East and Africa show growing interest in advanced therapeutics, with infrastructure, specialist access, and regulatory capacity varying considerably across markets.

Group Insights: Economic and Strategic Blocs Shape Adoption

ASEAN countries offer a diverse combination of emerging healthcare systems, regional clinical collaboration, and differing regulatory pathways. BRICS members provide substantial scientific, manufacturing, and patient-population capabilities, although policy and access conditions differ across the group. The European Union benefits from shared regulatory coordination alongside national reimbursement decisions. G7 members generally combine advanced research ecosystems with demanding evidence and health-technology assessment requirements. GCC countries are strengthening specialized care and international research linkages, while NATO members span mature and developing biomedical systems whose collaboration can support resilience in clinical supply and research networks.

Country Insights: Distinct Research, Access, and Regulatory Conditions

The United States and Canada offer deep translational research capabilities and specialized clinical centers. Germany, France, Italy, Spain, and the United Kingdom combine established life-science expertise with structured regulatory and reimbursement evaluation. China, Japan, and South Korea are important Asian research and clinical-development environments, each with distinct approval and evidence requirements. Australia supports investigator-led studies and regional clinical collaboration. India contributes growing pharmaceutical, clinical, and scientific capacity. Brazil and Mexico are influential Latin American settings for clinical research and access planning. Russia requires careful consideration of regulatory, operational, and international-collaboration conditions when assessing development pathways.

Priorities for Leaders Developing Integrin-Inhibitor Programs

Industry leaders should define the disease mechanism and integrin subtype before selecting a development path, then link each program to measurable pharmacodynamic and clinical biomarkers. Safety planning should address tissue-specific biology, immune effects, infection risk where relevant, and the possibility of pathway compensation. Development teams should build regulatory and reimbursement evidence requirements into trial design, use adaptive learning where scientifically justified, and establish region-specific operating plans. Partnerships with diagnostic, data-science, and clinical research specialists can strengthen patient identification and translational execution. AI initiatives should begin with clearly governed use cases and predefined validation standards.

Research Methodology for the Executive Summary

This summary uses the supplied market definition-integrin inhibitors-as its analytical scope and organizes the discussion around therapeutic biology, development trends, artificial intelligence, geography, and strategic implications. Regional, group, and country perspectives are qualitative and based on publicly observable characteristics of biomedical research, healthcare infrastructure, regulation, and clinical-development capacity. No market estimates, market shares, forecasts, or company-specific claims are used. Conclusions should be validated against current peer-reviewed literature, clinical-trial registries, regulatory publications, reimbursement decisions, and country-level healthcare data before operational use.

Conclusion: Precision and Evidence Will Define Progress

Integrin inhibitors remain a biologically differentiated field in which therapeutic value depends on matching the right integrin mechanism to the right disease and patient population. Progress will be determined by selective pharmacology, credible biomarkers, disciplined safety management, and evidence that translates across regulatory and healthcare settings. Organizations that combine mechanistic rigor with data-enabled development and regionally informed execution will be better positioned to advance programs responsibly.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Integrin Inhibitors Market, by Indication
7.1. Introduction
7.2. Crohn Disease
7.2.1. Fistulizing
7.2.2. Inflammatory
7.2.3. Stricturing
7.3. Multiple Sclerosis
7.4. Psoriasis
7.4.1. Guttate Psoriasis
7.4.2. Inverse Psoriasis
7.4.3. Plaque Psoriasis
7.4.4. Pustular Psoriasis
7.5. Ulcerative Colitis
8. Integrin Inhibitors Market, by Molecule Type
8.1. Introduction
8.2. Monoclonal Antibodies
8.3. Peptide Inhibitors
8.3.1. Cyclic Peptides
8.3.2. Linear Peptides
8.4. Small Molecules
8.4.1. Ligand Mimetics
8.4.2. Receptor Antagonists
9. Integrin Inhibitors Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.3.1. Capsules
9.3.2. Tablets
9.4. Subcutaneous
10. Integrin Inhibitors Market, by End User
10.1. Introduction
10.2. Home Care Settings
10.2.1. Home Nursing Services
10.2.2. Self Administration
10.3. Hospitals
10.3.1. Private Hospitals
10.3.2. Public Hospitals
10.4. Specialty Clinics
10.4.1. Dermatology Clinics
10.4.2. Gastroenterology Clinics
10.4.3. Neurology Clinics
11. Integrin Inhibitors Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Integrin Inhibitors Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Integrin Inhibitors Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. AbbVie Inc.
15.2. Akeso Biopharma Inc.
15.3. AlloCyte Pharmaceuticals AG
15.4. Almirall, S.A.
15.5. Amgen Inc.
15.6. Astellas Pharma Inc.
15.7. AstraZeneca PLC
15.8. Bayer AG
15.9. Biogen Inc.
15.10. Bristol-Myers Squibb Company
15.11. ChemoCentryx, Inc.
15.12. Eli Lilly and Company
15.13. Encycle Therapeutics, Inc.
15.14. Ensho Therapeutics, Inc.
15.15. Gilead Sciences, Inc.
15.16. GlaxoSmithKline PLC
15.17. Janssen Biotech, Inc.
15.18. Merck & Co., Inc.
15.19. Morphic Therapeutic, Inc.
15.20. Pfizer Inc.
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Integrin Inhibitors Market, Years Considered for the Study
FIGURE 2. Global Integrin Inhibitors Market, Research Design
FIGURE 3. Global Integrin Inhibitors Market, Research Framework
FIGURE 4. Global Integrin Inhibitors Market, Data Triangulation
FIGURE 5. Global Integrin Inhibitors Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Integrin Inhibitors Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 7. Global Integrin Inhibitors Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Integrin Inhibitors Market Size, by Molecule Type, 2025 vs 2032 (%)
FIGURE 9. Global Integrin Inhibitors Market Size, by Molecule Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Integrin Inhibitors Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Integrin Inhibitors Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Integrin Inhibitors Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Integrin Inhibitors Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Integrin Inhibitors Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Integrin Inhibitors Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Integrin Inhibitors Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Integrin Inhibitors Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Integrin Inhibitors Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Integrin Inhibitors Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Integrin Inhibitors Market Segmentation & Coverage
TABLE 2. Global Integrin Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 3. Global Integrin Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 4. Global Crohn Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Crohn Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Crohn Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Fistulizing Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Fistulizing Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Fistulizing Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Inflammatory Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Inflammatory Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Inflammatory Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Stricturing Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Stricturing Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Stricturing Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Multiple Sclerosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Multiple Sclerosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Multiple Sclerosis Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Psoriasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Psoriasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Psoriasis Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Guttate Psoriasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Guttate Psoriasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Guttate Psoriasis Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Inverse Psoriasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Inverse Psoriasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Inverse Psoriasis Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Plaque Psoriasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Plaque Psoriasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Plaque Psoriasis Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Pustular Psoriasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Pustular Psoriasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Pustular Psoriasis Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Ulcerative Colitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Ulcerative Colitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Ulcerative Colitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Integrin Inhibitors Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 38. Global Monoclonal Antibodies Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Monoclonal Antibodies Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Monoclonal Antibodies Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Peptide Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Peptide Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Peptide Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Cyclic Peptides Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Cyclic Peptides Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Cyclic Peptides Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Linear Peptides Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Linear Peptides Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Linear Peptides Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Small Molecules Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Small Molecules Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Small Molecules Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Ligand Mimetics Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Ligand Mimetics Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Ligand Mimetics Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Receptor Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Receptor Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Receptor Antagonists Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Integrin Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 60. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Capsules Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Capsules Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Capsules Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Tablets Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Integrin Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 76. Global Home Care Settings Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Home Care Settings Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Home Care Settings Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Home Nursing Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Home Nursing Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Home Nursing Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global Self Administration Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global Self Administration Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global Self Administration Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 88. Global Private Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Private Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Private Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global Public Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Global Public Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. Global Public Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 94. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 97. Global Dermatology Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Global Dermatology Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 99. Global Dermatology Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 100. Global Gastroenterology Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Global Gastroenterology Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 102. Global Gastroenterology Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 103. Global Neurology Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Global Neurology Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. Global Neurology Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 106. Global Integrin Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Asia-Pacific Integrin Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 108. Asia-Pacific Integrin Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 109. Asia-Pacific Integrin Inhibitors Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 110. Asia-Pacific Integrin Inhibitors Market Size, by Psoriasis, 2017-2032 (USD Million)
TABLE 111. Asia-Pacific Integrin Inhibitors Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 112. Asia-Pacific Integrin Inhibitors Market Size, by Peptide Inhibitors, 2017-2032 (USD Million)
TABLE 113. Asia-Pacific Integrin Inhibitors Market Size, by Small Molecules, 2017-2032 (USD Million)
TABLE 114. Asia-Pacific Integrin Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 115. Asia-Pacific Integrin Inhibitors Market Size, by Oral, 2017-2032 (USD Million)
TABLE 116. Asia-Pacific Integrin Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 117. Asia-Pacific Integrin Inhibitors Market Size, by Home Care Settings, 2017-2032 (USD Million)
TABLE 118. Asia-Pacific Integrin Inhibitors Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 119. Asia-Pacific Integrin Inhibitors Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 120. North America Integrin Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 121. North America Integrin Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 122. North America Integrin Inhibitors Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 123. North America Integrin Inhibitors Market Size, by Psoriasis, 2017-2032 (USD Million)
TABLE 124. North America Integrin Inhibitors Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 125. North America Integrin Inhibitors Market Size, by Peptide Inhibitors, 2017-2032 (USD Million)
TABLE 126. North America Integrin Inhibitors Market Size, by Small Molecules, 2017-2032 (USD Million)
TABLE 127. North America Integrin Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 128. North America Integrin Inhibitors Market Size, by Oral, 2017-2032 (USD Million)
TABLE 129. North America Integrin Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 130. North America Integrin Inhibitors Market Size, by Home Care Settings, 2017-2032 (USD Million)
TABLE 131. North America Integrin Inhibitors Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 132. North America Integrin Inhibitors Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 133. Latin America Integrin Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 134. Latin America Integrin Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 135. Latin America Integrin Inhibitors Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 136. Latin America Integrin Inhibitors Market Size, by Psoriasis, 2017-2032 (USD Million)
TABLE 137. Latin America Integrin Inhibitors Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 138. Latin America Integrin Inhibitors Market Size, by Peptide Inhibitors, 2017-2032 (USD Million)
TABLE 139. Latin America Integrin Inhibitors Market Size, by Small Molecules, 2017-2032 (USD Million)
TABLE 140. Latin America Integrin Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 141. Latin America Integrin Inhibitors Market Size, by Oral, 2017-2032 (USD Million)
TABLE 142. Latin America Integrin Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 143. Latin America Integrin Inhibitors Market Size, by Home Care Settings, 2017-2032 (USD Million)
TABLE 144. Latin America Integrin Inhibitors Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 145. Latin America Integrin Inhibitors Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 146. Europe Integrin Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 147. Europe Integrin Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 148. Europe Integrin Inhibitors Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 149. Europe Integrin Inhibitors Market Size, by Psoriasis, 2017-2032 (USD Million)
TABLE 150. Europe Integrin Inhibitors Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 151. Europe Integrin Inhibitors Market Size, by Peptide Inhibitors, 2017-2032 (USD Million)
TABLE 152. Europe Integrin Inhibitors Market Size, by Small Molecules, 2017-2032 (USD Million)
TABLE 153. Europe Integrin Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 154. Europe Integrin Inhibitors Market Size, by Oral, 2017-2032 (USD Million)
TABLE 155. Europe Integrin Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 156. Europe Integrin Inhibitors Market Size, by Home Care Settings, 2017-2032 (USD Million)
TABLE 157. Europe Integrin Inhibitors Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 158. Europe Integrin Inhibitors Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 159. Middle East Integrin Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 160. Middle East Integrin Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 161. Middle East Integrin Inhibitors Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 162. Middle East Integrin Inhibitors Market Size, by Psoriasis, 2017-2032 (USD Million)
TABLE 163. Middle East Integrin Inhibitors Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 164. Middle East Integrin Inhibitors Market Size, by Peptide Inhibitors, 2017-2032 (USD Million)
TABLE 165. Middle East Integrin Inhibitors Market Size, by Small Molecules, 2017-2032 (USD Million)
TABLE 166. Middle East Integrin Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 167. Middle East Integrin Inhibitors Market Size, by Oral, 2017-2032 (USD Million)
TABLE 168. Middle East Integrin Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 169. Middle East Integrin Inhibitors Market Size, by Home Care Settings, 2017-2032 (USD Million)
TABLE 170. Middle East Integrin Inhibitors Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 171. Middle East Integrin Inhibitors Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 172. Africa Integrin Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 173. Africa Integrin Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 174. Africa Integrin Inhibitors Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 175. Africa Integrin Inhibitors Market Size, by Psoriasis, 2017-2032 (USD Million)
TABLE 176. Africa Integrin Inhibitors Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 177. Africa Integrin Inhibitors Market Size, by Peptide Inhibitors, 2017-2032 (USD Million)
TABLE 178. Africa Integrin Inhibitors Market Size, by Small Molecules, 2017-2032 (USD Million)
TABLE 179. Africa Integrin Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 180. Africa Integrin Inhibitors Market Size, by Oral, 2017-2032 (USD Million)
TABLE 181. Africa Integrin Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 182. Africa Integrin Inhibitors Market Size, by Home Care Settings, 2017-2032 (USD Million)
TABLE 183. Africa Integrin Inhibitors Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 184. Africa Integrin Inhibitors Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 185. Global Integrin Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 186. ASEAN Integrin Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 187. ASEAN Integrin Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 188. ASEAN Integrin Inhibitors Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 189. ASEAN Integrin Inhibitors Market Size, by Psoriasis, 2017-2032 (USD Million)
TABLE 190. ASEAN Integrin Inhibitors Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 191. ASEAN Integrin Inhibitors Market Size, by Peptide Inhibitors, 2017-2032 (USD Million)
TABLE 192. ASEAN Integrin Inhibitors Market Size, by Small Molecules, 2017-2032 (USD Million)
TABLE 193. ASEAN Integrin Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 194. ASEAN Integrin Inhibitors Market Size, by Oral, 2017-2032 (USD Million)
TABLE 195. ASEAN Integrin Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 196. ASEAN Integrin Inhibitors Market Size, by Home Care Settings, 2017-2032 (USD Million)
TABLE 197. ASEAN Integrin Inhibitors Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 198. ASEAN Integrin Inhibitors Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 199. GCC Integrin Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 200. GCC Integrin Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 201. GCC Integrin Inhibitors Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 202. GCC Integrin Inhibitors Market Size, by Psoriasis, 2017-2032 (USD Million)
TABLE 203. GCC Integrin Inhibitors Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 204. GCC Integrin Inhibitors Market Size, by Peptide Inhibitors, 2017-2032 (USD Million)
TABLE 205. GCC Integrin Inhibitors Market Size, by Small Molecules, 2017-2032 (USD Million)
TABLE 206. GCC Integrin Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 207. GCC Integrin Inhibitors Market Size, by Oral, 2017-2032 (USD Million)
TABLE 208. GCC Integrin Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 209. GCC Integrin Inhibitors Market Size, by Home Care Settings, 2017-2032 (USD Million)
TABLE 210. GCC Integrin Inhibitors Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 211. GCC Integrin Inhibitors Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 212. European Union Integrin Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 213. European Union Integrin Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 214. European Union Integrin Inhibitors Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 215. European Union Integrin Inhibitors Market Size, by Psoriasis, 2017-2032 (USD Million)
TABLE 216. European Union Integrin Inhibitors Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 217. European Union Integrin Inhibitors Market Size, by Peptide Inhibitors, 2017-2032 (USD Million)
TABLE 218. European Union Integrin Inhibitors Market Size, by Small Molecules, 2017-2032 (USD Million)
TABLE 219. European Union Integrin Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 220. European Union Integrin Inhibitors Market Size, by Oral, 2017-2032 (USD Million)
TABLE 221. European Union Integrin Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 222. European Union Integrin Inhibitors Market Size, by Home Care Settings, 2017-2032 (USD Million)
TABLE 223. European Union Integrin Inhibitors Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 224. European Union Integrin Inhibitors Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 225. BRICS Integrin Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 226. BRICS Integrin Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 227. BRICS Integrin Inhibitors Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 228. BRICS Integrin Inhibitors Market Size, by Psoriasis, 2017-2032 (USD Million)
TABLE 229. BRICS Integrin Inhibitors Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 230. BRICS Integrin Inhibitors Market Size, by Peptide Inhibitors, 2017-2032 (USD Million)
TABLE 231. BRICS Integrin Inhibitors Market Size, by Small Molecules, 2017-2032 (USD Million)
TABLE 232. BRICS Integrin Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 233. BRICS Integrin Inhibitors Market Size, by Oral, 2017-2032 (USD Million)
TABLE 234. BRICS Integrin Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 235. BRICS Integrin Inhibitors Market Size, by Home Care Settings, 2017-2032 (USD Million)
TABLE 236. BRICS Integrin Inhibitors Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 237. BRICS Integrin Inhibitors Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 238. G7 Integrin Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 239. G7 Integrin Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 240. G7 Integrin Inhibitors Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 241. G7 Integrin Inhibitors Market Size, by Psoriasis, 2017-2032 (USD Million)
TABLE 242. G7 Integrin Inhibitors Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 243. G7 Integrin Inhibitors Market Size, by Peptide Inhibitors, 2017-2032 (USD Million)
TABLE 244. G7 Integrin Inhibitors Market Size, by Small Molecules, 2017-2032 (USD Million)
TABLE 245. G7 Integrin Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 246. G7 Integrin Inhibitors Market Size, by Oral, 2017-2032 (USD Million)
TABLE 247. G7 Integrin Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 248. G7 Integrin Inhibitors Market Size, by Home Care Settings, 2017-2032 (USD Million)
TABLE 249. G7 Integrin Inhibitors Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 250. G7 Integrin Inhibitors Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 251. NATO Integrin Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 252. NATO Integrin Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 253. NATO Integrin Inhibitors Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 254. NATO Integrin Inhibitors Market Size, by Psoriasis, 2017-2032 (USD Million)
TABLE 255. NATO Integrin Inhibitors Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 256. NATO Integrin Inhibitors Market Size, by Peptide Inhibitors, 2017-2032 (USD Million)
TABLE 257. NATO Integrin Inhibitors Market Size, by Small Molecules, 2017-2032 (USD Million)
TABLE 258. NATO Integrin Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 259. NATO Integrin Inhibitors Market Size, by Oral, 2017-2032 (USD Million)
TABLE 260. NATO Integrin Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 261. NATO Integrin Inhibitors Market Size, by Home Care Settings, 2017-2032 (USD Million)
TABLE 262. NATO Integrin Inhibitors Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 263. NATO Integrin Inhibitors Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 264. Global Integrin Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 265. United States Integrin Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 266. United States Integrin Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 267. United States Integrin Inhibitors Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 268. United States Integrin Inhibitors Market Size, by Psoriasis, 2017-2032 (USD Million)
TABLE 269. United States Integrin Inhibitors Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 270. United States Integrin Inhibitors Market Size, by Peptide Inhibitors, 2017-2032 (USD Million)
TABLE 271. United States Integrin Inhibitors Market Size, by Small Molecules, 2017-2032 (USD Million)
TABLE 272. United States Integrin Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 273. United States Integrin Inhibitors Market Size, by Oral, 2017-2032 (USD Million)
TABLE 274. United States Integrin Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 275. United States Integrin Inhibitors Market Size, by Home Care Settings, 2017-2032 (USD Million)
TABLE 276. United States Integrin Inhibitors Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 277. United States Integrin Inhibitors Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 278. Canada Integrin Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 279. Canada Integrin Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 280. Canada Integrin Inhibitors Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 281. Canada Integrin Inhibitors Market Size, by Psoriasis, 2017-2032 (USD Million)
TABLE 282. Canada Integrin Inhibitors Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 283. Canada Integrin Inhibitors Market Size, by Peptide Inhibitors, 2017-2032 (USD Million)
TABLE 284. Canada Integrin Inhibitors Market Size, by Small Molecules, 2017-2032 (USD Million)
TABLE 285. Canada Integrin Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 286. Canada Integrin Inhibitors Market Size, by Oral, 2017-2032 (USD Million)
TABLE 287. Canada Integrin Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 288. Canada Integrin Inhibitors Market Size, by Home Care Settings, 2017-2032 (USD Million)
TABLE 289. Canada Integrin Inhibitors Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 290. Canada Integrin Inhibitors Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 291. Mexico Integrin Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 292. Mexico Integrin Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 293. Mexico Integrin Inhibitors Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 294. Mexico Integrin Inhibitors Market Size, by Psoriasis, 2017-2032 (USD Million)
TABLE 295. Mexico Integrin Inhibitors Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 296. Mexico Integrin Inhibitors Market Size, by Peptide Inhibitors, 2017-2032 (USD Million)
TABLE 297. Mexico Integrin Inhibitors Market Size, by Small Molecules, 2017-2032 (USD Million)
TABLE 298. Mexico Integrin Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 299. Mexico Integrin Inhibitors Market Size, by Oral, 2017-2032 (USD Million)
TABLE 300. Mexico Integrin Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 301. Mexico Integrin Inhibitors Market Size, by Home Care Settings, 2017-2032 (USD Million)
TABLE 302. Mexico Integrin Inhibitors Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 303. Mexico Integrin Inhibitors Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 304. Brazil Integrin Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 305. Brazil Integrin Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 306. Brazil Integrin Inhibitors Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 307. Brazil Integrin Inhibitors Market Size, by Psoriasis, 2017-2032 (USD Million)
TABLE 308. Brazil Integrin Inhibitors Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 309. Brazil Integrin Inhibitors Market Size, by Peptide Inhibitors, 2017-2032 (USD Million)
TABLE 310. Brazil Integrin Inhibitors Market Size, by Small Molecules, 2017-2032 (USD Million)
TABLE 311. Brazil Integrin Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 312. Brazil Integrin Inhibitors Market Size, by Oral, 2017-2032 (USD Million)
TABLE 313. Brazil Integrin Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 314. Brazil Integrin Inhibitors Market Size, by Home Care Settings, 2017-2032 (USD Million)
TABLE 315. Brazil Integrin Inhibitors Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 316. Brazil Integrin Inhibitors Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 317. United Kingdom Integrin Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 318. United Kingdom Integrin Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 319. United Kingdom Integrin Inhibitors Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 320. United Kingdom Integrin Inhibitors Market Size, by Psoriasis, 2017-2032 (USD Million)
TABLE 321. United Kingdom Integrin Inhibitors Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 322. United Kingdom Integrin Inhibitors Market Size, by Peptide Inhibitors, 2017-2032 (USD Million)
TABLE 323. United Kingdom Integrin Inhibitors Market Size, by Small Molecules, 2017-2032 (USD Million)
TABLE 324. United Kingdom Integrin Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 325. United Kingdom Integrin Inhibitors Market Size, by Oral, 2017-2032 (USD Million)
TABLE 326. United Kingdom Integrin Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 327. United Kingdom Integrin Inhibitors Market Size, by Home Care Settings, 2017-2032 (USD Million)
TABLE 328. United Kingdom Integrin Inhibitors Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 329. United Kingdom Integrin Inhibitors Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 330. Germany Integrin Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 331. Germany Integrin Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 332. Germany Integrin Inhibitors Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 333. Germany Integrin Inhibitors Market Size, by Psoriasis, 2017-2032 (USD Million)
TABLE 334. Germany Integrin Inhibitors Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 335. Germany Integrin Inhibitors Market Size, by Peptide Inhibitors, 2017-2032 (USD Million)
TABLE 336. Germany Integrin Inhibitors Market Size, by Small Molecules, 2017-2032 (USD Million)
TABLE 337. Germany Integrin Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 338. Germany Integrin Inhibitors Market Size, by Oral, 2017-2032 (USD Million)
TABLE 339. Germany Integrin Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 340. Germany Integrin Inhibitors Market Size, by Home Care Settings, 2017-2032 (USD Million)
TABLE 341. Germany Integrin Inhibitors Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 342. Germany Integrin Inhibitors Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 343. France Integrin Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 344. France Integrin Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 345. France Integrin Inhibitors Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 346. France Integrin Inhibitors Market Size, by Psoriasis, 2017-2032 (USD Million)
TABLE 347. France Integrin Inhibitors Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 348. France Integrin Inhibitors Market Size, by Peptide Inhibitors, 2017-2032 (USD Million)
TABLE 349. France Integrin Inhibitors Market Size, by Small Molecules, 2017-2032 (USD Million)
TABLE 350. France Integrin Inhibitors Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 351. France Integrin Inhibitors Market Size, by Oral, 2017-2032 (USD Million)
TABLE 352. France Integrin Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 353. France Integrin Inhibitors Market Size, by Home Care Settings, 2017-2032 (USD Million)
TABLE 354. France Integrin Inhibitors Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 355. France Integrin Inhibitors Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 356. Russia Integrin Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 357. Russia Integrin Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 358. Russia Integrin Inhibitors Market Size, by Crohn Disease, 2017-2032 (USD Million)
TABLE 359. Russia Integrin Inhibitors Market Size, by Psoriasis, 2017-2032 (USD Million)
TABLE 360. Russia Integrin Inhibitors Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 361. Russia Integrin Inhibitors Market Size, by Peptide Inhibitors, 2017-2032 (USD Million)
TABLE 362. Russia Integrin Inhibitors Market Size, by Small Molecules, 2017-2032 (USD Million)
TABLE 363. Russia Integrin Inhibitors Market Size, by Route Of Admini

Companies Mentioned

  • AbbVie Inc.
  • Akeso Biopharma Inc.
  • AlloCyte Pharmaceuticals AG
  • Almirall, S.A.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • ChemoCentryx, Inc.
  • Eli Lilly and Company
  • Encycle Therapeutics, Inc.
  • Ensho Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Janssen Biotech, Inc.
  • Merck & Co., Inc.
  • Morphic Therapeutic, Inc.
  • Pfizer Inc.

Related Topics

Related Reports

Ocular Immunosuppressants Market - Global Forecast 2026-2032 - Product Image

Ocular Immunosuppressants Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Crohn's Disease Therapeutics Market - Global Forecast 2026-2032 - Product Image

Crohn's Disease Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Inflammatory Bowel Disease Treatment Market Report by Drug Class, Disease Indication, Distribution Channel, Country and Company Analysis 2026-2034 - Product Image

Inflammatory Bowel Disease Treatment Market Report by Drug Class, Disease Indication, Distribution Channel, Country and Company Analysis 2026-2034

  • Report
  • 200 Pages
  • Global
From
Inflammatory Bowel Disease (IBD) Therapeutics - Global Strategic Business Report - Product Image

Inflammatory Bowel Disease (IBD) Therapeutics - Global Strategic Business Report

  • Report
  • 504 Pages
  • Global
From
Ulcerative Colitis Drug Market Outlook: Advanced Therapeutics, Pipeline Innovations, and Competitive Landscape - Product Image

Ulcerative Colitis Drug Market Outlook: Advanced Therapeutics, Pipeline Innovations, and Competitive Landscape

  • Report
  • 99 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.